Evidence map›Paper›PMID 34959681›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from

Romain Galy, Stéphanie Ballereau, Yves Génisson, Lionel Mourey, Jean-Christophe Plaquevent, Laurent Maveyraud

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Romain GalyInstitut de Pharmacologie et de Biologie Structurale, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31077 Toulouse, France.
Stéphanie BallereauLaboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31062 Toulouse, France.ORCID 0000-0002-7250-6188
Yves GénissonLaboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31062 Toulouse, France.
Lionel MoureyInstitut de Pharmacologie et de Biologie Structurale, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31077 Toulouse, France.ORCID 0000-0002-8259-1259
Jean-Christophe PlaqueventLaboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31062 Toulouse, France.
Laurent MaveyraudInstitut de Pharmacologie et de Biologie Structurale, Université Toulouse III-Paul Sabatier, Centre National de la Recherche Scientifique, 31077 Toulouse, France.ORCID 0000-0003-4610-8319
Université Toulouse III - Paul Sabatier · FR

Funding

French National Centre for Scientific Research N/AUniversité Paul Sabatier - Université de Toulouse N/A
6 · The paper itself

Abstract

The mycolic acid biosynthetic pathway represents a promising source of pharmacological targets in the fight against tuberculosis. In

Indexed as

binding energiesfragment-based ligand discoverymolecular modellingMycobacterium tuberculosismycolic acid methyltransferases

Identifiers

PMID34959681
PMCPMC8708032
OpenAlexW4200026273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.